These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9492815)

  • 1. Tumour necrosis factor and septic shock.
    Waage A
    Lancet; 1998 Feb; 351(9102):603. PubMed ID: 9492815
    [No Abstract]   [Full Text] [Related]  

  • 2. Not just cachectin involved in toxic shock.
    Billiau A
    Nature; 1988 Feb; 331(6158):665. PubMed ID: 3344042
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of septic shock with antibodies to tumour necrosis factor.
    Cohen J; Exley AR
    Schweiz Med Wochenschr; 1993 Mar; 123(11):492-6. PubMed ID: 8475356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
    Abraham E; Anzueto A; Gutierrez G; Tessler S; San Pedro G; Wunderink R; Dal Nogare A; Nasraway S; Berman S; Cooney R; Levy H; Baughman R; Rumbak M; Light RB; Poole L; Allred R; Constant J; Pennington J; Porter S
    Lancet; 1998 Mar; 351(9107):929-33. PubMed ID: 9734938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of septic shock: new approaches.
    Baumgartner JD; Eggimann P; Glauser MP
    Curr Clin Top Infect Dis; 1992; 12():165-87. PubMed ID: 1642798
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal antibody to TNFalpha in septic shock.
    Cohen J
    Lancet; 1998 Jun; 351(9117):1731. PubMed ID: 9734908
    [No Abstract]   [Full Text] [Related]  

  • 7. Search for effective immunomodulating strategies against sepsis.
    Vincent JL
    Lancet; 1998 Mar; 351(9107):922-3. PubMed ID: 9734931
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cytokines and septic shock. New perspectives on its treatment].
    Zamora Madaria E
    An Med Interna; 1993 Dec; 10(12):573-5. PubMed ID: 8049320
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy of sepsis and septic shock].
    Ivanović D; Gjurasin M; Gasparović V; Radonić R; Kvarantan M; Merkler M
    Lijec Vjesn; 1995 Jun; 117 Suppl 2():8-11. PubMed ID: 8649167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis.
    Opal SM; Cross AS; Sadoff JC; Collins HH; Kelly NM; Victor GH; Palardy JE; Bodmer MW
    J Clin Invest; 1991 Sep; 88(3):885-90. PubMed ID: 1885775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot clinical trial of an anti-TNF alpha monoclonal antibody for the treatment of septic shock.
    Boillot A; Capellier G; Racadot E; Wijdenes J; Herve P; Barale F
    Clin Intensive Care; 1995; 6(2):52-6. PubMed ID: 10150799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy with antibody to tumor necrosis factor in sepsis.
    Pennington JE
    Clin Infect Dis; 1993 Nov; 17 Suppl 2():S515-9. PubMed ID: 8274618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha).
    Hinshaw LB; Tekamp-Olson P; Chang AC; Lee PA; Taylor FB; Murray CK; Peer GT; Emerson TE; Passey RB; Kuo GC
    Circ Shock; 1990 Mar; 30(3):279-92. PubMed ID: 2178801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy in sepsis syndrome].
    Schellekens JF; van Deventer SJ
    Ned Tijdschr Geneeskd; 1992 May; 136(22):1050-4. PubMed ID: 1603159
    [No Abstract]   [Full Text] [Related]  

  • 17. Anticytokine strategies for the treatment of septic shock: relevance of animal models.
    Heumann D; Glauser MP
    Curr Top Microbiol Immunol; 1996; 216():299-311. PubMed ID: 8791746
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoclonal antibody to TNF in severe septic shock.
    Exley AR; Cohen J; Buurman W; Owen R; Hanson G; Lumley J; Aulakh JM; Bodmer M; Riddell A; Stephens S
    Lancet; 1990 May; 335(8700):1275-7. PubMed ID: 1971339
    [No Abstract]   [Full Text] [Related]  

  • 19. Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study.
    Vincent JL; Bakker J; Marécaux G; Schandene L; Kahn RJ; Dupont E
    Chest; 1992 Mar; 101(3):810-5. PubMed ID: 1541150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody.
    Hinshaw LB; Emerson TE; Taylor FB; Chang AC; Duerr M; Peer GT; Flournoy DJ; White GL; Kosanke SD; Murray CK
    J Trauma; 1992 Oct; 33(4):568-73. PubMed ID: 1433404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.